Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources

References

• Austin, P. C. 2011. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research 46 (3):399–424. doi:10.1080/00273171.2011.568786.
   PubMed Web of Science ®Google Scholar
• Chen, W.-C., C. Wang, H. Li, N. Lu, R. Tiwari, Y. Xu, and L. Q. Yue. 2020. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data. Journal of Biopharmaceutical Statistics 30 (3):508–520. doi:10.1080/10543406.2020.1730877.
   PubMed Web of Science ®Google Scholar
• D’Agostino, R. B., Jr, and D. B. Rubin. 2000. Estimating and using propensity scores with partially missing data. Journal of the American Statistical Association 95 (451):749–759. doi:10.1080/01621459.2000.10474263.
   Web of Science ®Google Scholar
• Gottlieb, S. 2018. FDA budget matters: a cross-cutting data enterprise for real world evidence. https://www.fda.gov/news-events/fda-voices/fda-budget-matters-cross-cutting-data-enterprise-real-world-evidenc
   Google Scholar
• Ibrahim, J. G., and M. H. Chen. 2000. Power prior distributions for regression models. Statistical Science 15:46–60.
   Web of Science ®Google Scholar
• Inman, H. F., and E. L. Bradley Jr. 1989. The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities. Communications in Statistics-Theory and Methods 18 (10):3851–3874. doi:10.1080/03610928908830127.
   Web of Science ®Google Scholar
• Lee, B. K., J. Lessler, and E. A. Stuart. 2010. Improving propensity score weighting using machine learning. Statistics in Medicine 29 (3):337–346. doi:10.1002/sim.3782.
   PubMed Web of Science ®Google Scholar
• Levenson, M., W. He, J. Chen, Y. Fang, D. Faries, B. A. Goldstein, M. Ho, K. Lee, P. Mishra-Kalyani, F. Rockhold, et al. 2021. Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment. Statistics in Biopharmaceutical Research 1–11. doi:10.1080/19466315.2021.1883473.
   Web of Science ®Google Scholar
• Li, H., V. Mukhi, N. Lu, Y.-L. Xu, and L. Q. Yue. 2016. A note on good practice of objective propensity score design for premarket nonrandomized medical device studies with an example. Statistics in Biopharmaceutical Research 8 (3):282–286. doi:10.1080/19466315.2016.1148071.
   Web of Science ®Google Scholar
• Lin, J., M. Gamalo-Siebers, and R. Tiwari. 2018a. Propensity-score-based priors for Bayesian augmented control design. Pharmaceutical Statistics 18 (2):223–238. doi:10.1002/pst.1918.
   PubMed Web of Science ®Google Scholar
• Lin, J., M. Gamalo-Siebers, and R. Tiwari. 2018b. Propensity score matched augmented controls in randomized clinical trials: A case study. Pharmaceutical Statistics 17 (5):629–647.
   PubMed Web of Science ®Google Scholar
• Lu, N., Y. Xu, and L. Yue. 2019. Good statistical practice in utilizing real world data in a comparative study for premarket evaluation of medical devices. Journal of Biopharmaceutical Statistics 29 (4):580–591. doi:10.1080/10543406.2019.1632880.
   PubMed Web of Science ®Google Scholar
• Lu, N., Y. Xu, and L. Yue. 2020. Some considerations on design and analysis plan on a nonrandomized comparative study utilizing propensity score methodology for medical device premarket evaluation. Statistics in Biopharmaceutical Research 12 (2):155–163. doi:10.1080/19466315.2019.1647873.
   Web of Science ®Google Scholar
• Lunceford, J. K., and M. Davidian. 2004. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Statistics in Medicine 23 (19):2937–2960. doi:10.1002/sim.v23:19.
   PubMed Web of Science ®Google Scholar
• Rosenbaum, P. R., and D. B. Rubin. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1):41–55. doi:10.1093/biomet/70.1.41.
   Web of Science ®Google Scholar
• Rosenbaum, P. R., and D. B. Rubin. 1984. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association 79 (387):516–524. doi:10.1080/01621459.1984.10478078.
   Web of Science ®Google Scholar
• Rubin, D. B. 1997. Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine 127 (8_Part_2):757–763. doi:10.7326/0003-4819-127-8_Part_2-199710151-00064.
   PubMed Web of Science ®Google Scholar
• Rubin, D. B. 2001. Using propensity scores to help design observational studies: Application to the tobacco litigation. Health Services and Outcomes Research Methodology 2 (3–4):169–188. doi:10.1023/A:1020363010465.
   Google Scholar
• Rubin, D. B. 2007. The design versus the analysis of observational studies for causal effects: Parallels with the design of randomized trials. Statistics in Medicine 26 (1):20–36. doi:10.1002/()1097-0258.
   PubMed Web of Science ®Google Scholar
• Rubin, D. B. 2008. For objective causal inference, design trumps analysis. The Annals of Applied Statistics 808–840. doi:10.1214/08-AOAS187.
   Web of Science ®Google Scholar
• Stuart, E. A. 2010. Matching methods for causal inference: A review and a look forward. Statistical Science: A Review Journal of the Institute of Mathematical Statistics 25 (1):1. doi:10.1214/09-STS313.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2017. Use of real-world evidence to support regulatory decision-making for medical devices - guidance for industry and food and drug administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
   Google Scholar
• Wang, C., H. Li, W.-C. Chen, N. Lu, R. Tiwari, Y. Xu, and L. Q. Yue. 2019. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies. Journal of Biopharmaceutical Statistics 29 (5):731–748. doi:10.1080/10543406.2019.1657133.
   PubMed Web of Science ®Google Scholar
• Wang, C., N. Lu, W.-C. Chen, H. Li, R. Tiwari, Y. Xu, and L. Q. Yue. 2020. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies. Journal of Biopharmaceutical Statistics 30 (3):495–507. doi:10.1080/10543406.2019.1684309.
   PubMed Web of Science ®Google Scholar
• Xu, Y., N. Lu, L. Yue, and R. Tiwari. 2020. A study design for augmenting the control group in a randomized controlled trial: A quality process. Therapeutic Innovation & Regulatory Science 54 (2):269–274. doi:10.1177/2168479019830385.
   PubMed Web of Science ®Google Scholar
• Yue, L. Q., G. Campbell, N. Lu, Y. Xu, and B. Zuckerman. 2016. Utilizing national and international registries to enhance pre-market medical device regulatory evaluation. Journal of Biopharmaceutical Statistics 26 (6):1136–1145. doi:10.1080/10543406.2016.1226336.
   PubMed Web of Science ®Google Scholar
• Yue, L. Q., N. Lu, and Y. Xu. 2014. Designing premarket observational comparative studies using existing data as controls: Challenges and opportunities. Journal of Biopharmaceutical Statistics 24 (5):994–1010. doi:10.1080/10543406.2014.926367.
   PubMed Web of Science ®Google Scholar